MSCs have not fully delivered in the clinic yet. Poor cell viability and suboptimal secretion of factors hampers response efficacy in most settings. Gistem is realising the therapeutic potential of hUCECs´s extracellular vesicles (EVs) and their secretome through disease-specific formulation platforms.
GiStem´s approach overcomes problems associated with MSCs:
Accessible. Non-aggressive isolation of cells.
Scalable. Easy expansion of cells.
Effective. Stable regenerative and immunoregulatory therapeutic activities.